Market capitalization | $209.12m |
Enterprise Value | $36.00m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.09 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-42.31m |
Free Cash Flow (TTM) Free Cash Flow | $-29.19m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast XBiotech, Inc.:
1 Analyst has issued a forecast XBiotech, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.74 -1.74 |
18%
18%
|
|
EBITDA | -41 -41 |
15%
15%
|
EBIT (Operating Income) EBIT | -42 -42 |
14%
14%
|
Net Profit | -33 -33 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
XBiotech, Inc. is a biopharmaceutical company. The firm engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
Head office | Canada |
CEO | John Simard |
Employees | 82 |
Founded | 2005 |
Website | www.xbiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.